美邦科技(832471) - 投资者关系活动记录表

Group 1: Investor Relations Activity Overview - The investor relations activity was held on October 15, 2024, via an online platform [2] - Participants included the company's chairman, general manager, vice president, and financial officer [2] Group 2: Key Questions and Responses - Question regarding the R&D and market development status of β-Nicotinamide Mononucleotide (NMN) products was addressed, confirming that the subsidiary has completed the enzyme process development and is optimizing parameters [3] - Inquiry about the core technologies of the subsidiary, including gene editing, synthetic biology, and enzyme engineering, was answered, highlighting the development of various products such as Nylon 56 and Glutathione (GSH) [4]